Daridorexant, a medication used to treat insomnia, has a synthesis route that is protected by several patents. These patents are crucial for the drug's manufacturer, Idorsia Pharmaceuticals, as they provide market exclusivity.
How are patents protecting Daridorexant's synthesis?
The synthesis of daridorexant involves specific chemical processes and intermediate compounds, and patents are filed to cover these novel aspects [1]. These intellectual property protections aim to prevent competitors from using the same or similar manufacturing methods to produce generic versions of the drug. DrugPatentWatch.com tracks such patents, offering detailed information on pharmaceutical intellectual property [2].
When do Daridorexant's patents expire?
The expiration dates of patents for daridorexant's synthesis route are critical for determining when generic competition may enter the market. Pharmaceutical patents can have varying terms, and some may extend beyond the primary compound patent, covering specific manufacturing processes or polymorphs. Information on patent expiry can be found on specialized databases like DrugPatentWatch.com [2].
What are the potential challenges to Daridorexant's synthesis patents?
Companies seeking to introduce generic versions of daridorexant may challenge the validity or inventiveness of the synthesis route patents. These challenges can involve demonstrating that the patented processes are obvious, not novel, or that they were already known before the patent was filed. Litigation surrounding these patents can be complex and lengthy.
What are alternative synthesis methods for daridorexant?
While the patented synthesis route offers Idorsia Pharmaceuticals exclusivity, researchers may explore alternative chemical pathways to produce daridorexant. Developing a novel and non-infringing synthesis route is a common strategy for generic manufacturers, provided it is economically viable and meets regulatory standards.
Who manufactures Daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [1].
What is the regulatory status of Daridorexant?
Daridorexant has received approval from regulatory agencies for its indicated use, which is the treatment of insomnia [1].
What is the clinical significance of Daridorexant?
Daridorexant is a dual orexin receptor antagonist that works by blocking the wake-promoting signaling of orexins in the brain, thereby facilitating sleep [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/